← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	2,765	+182	+7%	$234B
2	2 Pfizer PFE $169B	2,404	+148	+7%	$197B
3	3 Merck MRK $365B	2,251	+195	+9%	$152B
4	4 AbbVie ABBV $506B	2,063	+107	+5%	$96.3B
5	5 Amgen AMGN $238B	1,892	+96	+5%	$96.2B
6	6 Bristol-Myers Squibb BMY $125B	1,766	+37	+2%	$63.2B
7	7 Gilead Sciences GILD $198B	1,498	-30	-2%	$64.1B
8	8 Novartis NVS $287B	1,088	+60	+6%	$23.4B
9	9 GSK GSK $98.6B	800	+13	+2%	$10.5B
10	10 Regeneron Pharmaceuticals REGN $82.6B	671	+27	+4%	$27.4B
11	11 AstraZeneca AZN $259B	558	+13	+2%	$17.7B
12	12 Incyte INCY $23.1B	454	-8	-2%	$12.5B
13	13 Jazz Pharmaceuticals JAZZ $13.9B	417	+14	+3%	$6.57B
14	14 DELISTED Exact Sciences EXAS	370	+6	+2%	$7.11B
15	15 Exelixis EXEL $15.5B	345	+28	+9%	$4.51B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	308	-22	-7%	$9.28B
17	17 Myriad Genetics MYGN $419M	264	-20	-7%	$2.22B
18	18 Qiagen QGEN $9.56B	252	+6	+2%	$4.97B
19	19 NeoGenomics NEO $2.21B	210	+43	+26%	$923M
20	20 Opko Health OPK $1.13B	202	-1	-0.5%	$428M
21	21 Kyntra Bio KYNB $22.4M	201	+14	+7%	$2.63B
22	22 DELISTED Immunogen Inc IMGN	200	-8	-4%	$589M
23	23 Halozyme HALO $13.8B	195	+2	+1%	$1.77B
24	24 BeOne Medicines Ltd ONC $42.2B	192	+48	+33%	$6.66B
25	25 DELISTED Eagle Pharmaceuticals, Inc. EGRX	182	-7	-4%	$570M